Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response

17 Aug 2024

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Cancer Cells and Metastasis
Share to Cancer Research and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39155193
DOI: 10.1016/j.eururo.2024.05.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine ResponsePMID 39155193Read ↗

Bladder cancer organoids as a functional system to model different disease stages and therapy responseSemantic proximity Read ↗

Bladder cancer organoids as a functional system to model different disease stages and therapy responseSemantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

Bladder cancer organoids as a functional system to model different disease stages and therapy responseSemantic proximity Read ↗

A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapySemantic proximity Read ↗

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.Semantic proximity Read ↗

Patient‐Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug ScreeningSemantic proximity Read ↗

A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid cultureSemantic proximity Read ↗

Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancerSemantic proximity Read ↗

Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoidsSemantic proximity Read ↗

Guidance of adjuvant instillation in intermediate risk non- muscle invasive bladder cancer by drug screens in patient derived organoids. A Single center, Open-label, Phase II trial. GAIN-INST-TrialSemantic proximity Read ↗

Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug RepurposingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.